Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 9/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18561550 | 1.00 | P2RY6 (0.49) | P2RY6P2RY14NT5EDNPH1TK2 | |
| SCHEMBL14853768 | 0.88 | P2RY6 (0.58) | P2RY6P2RY14P2RY2P2RY4 | |
| SCHEMBL14929325 | 0.88 | P2RY6 (0.50) | P2RY6P2RY14NT5EDNPH1TK2 | |
| SCHEMBL14946369 | 0.86 | TK2 (0.64) | TK2P2RY2 | |
| SCHEMBL14929508 | 0.86 | TK2 (0.64) | TK2P2RY2 | |
| SCHEMBL20456372 | 0.86 | TK2 (0.64) | TK2P2RY2 | |
| SCHEMBL14948888 | 0.83 | TK2 (0.54) | P2RY6P2RY14NT5EDNPH1TK2 | |
| SCHEMBL18573990 | 0.81 | TK2 (0.52) | P2RY6P2RY14NT5EDNPH1TK2 | |
| SCHEMBL14946353 | 0.81 | TK2 (0.52) | P2RY6P2RY14NT5EDNPH1TK2 | |
| SCHEMBL14929431 | 0.81 | TK2 (0.52) | P2RY6P2RY14NT5EDNPH1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY6 339/4885P2RY14 531/4885NT5E 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.